0001179110-18-003533.txt : 20180305
0001179110-18-003533.hdr.sgml : 20180305
20180305180725
ACCESSION NUMBER: 0001179110-18-003533
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180301
FILED AS OF DATE: 20180305
DATE AS OF CHANGE: 20180305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Haviland Kate
CENTRAL INDEX KEY: 0001663022
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37359
FILM NUMBER: 18667887
MAIL ADDRESS:
STREET 1: BLUEPRINT MEDICINES CORPORATION
STREET 2: 38 SIDNEY STREET, SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Blueprint Medicines Corp
CENTRAL INDEX KEY: 0001597264
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 45 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-374-7580
MAIL ADDRESS:
STREET 1: 45 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2018-03-01
0
0001597264
Blueprint Medicines Corp
BPMC
0001663022
Haviland Kate
C/O BLUEPRINT MEDICINES CORPORATION
45 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
Chief Business Officer
Common Stock
2018-03-01
4
M
0
2800
36.05
A
8674
D
Common Stock
2018-03-01
4
S
0
2800
90.00
D
5874
D
Stock Option (Right to Buy)
36.05
2018-03-01
4
M
0
2800
0
D
2027-02-16
Common Stock
2800
122210
D
The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.
/s/ Christopher Frankenfield, Attorney-in-Fact
2018-03-05